Latest research on Insulin detemir

Insulin detemir is a long-acting human insulin analogue used to maintain basal levels of insulin in diabetic individuals. It is produced using recombinant DNA technology in yeast cells. This insulin analogue has a 14-C fatty acid, myristic acid, bound to the lysine amino acid at position B29. The myristoyl side chain increases self-association and albumin binding. This along with slow systemic absorption from the injection site prolongs distribution of the hormone into tissues and results in a long duration of action. Novo Nordisk markets insulin detemir under the trade name Levemir.

Insulin detemir indications

But the A1Chieve,9 a metacentric non-interventional study on 60000 diabetics in 28 countries, across 4 continents, over 24-weeks, evaluated the safety and effectiveness of Insulin detemir, biphasic insulin Aspart, and insulin Aspart (Novo Nordisk Inc., Plainsboro, NJ, USA), in people with type 2 diabetes mellitus, concluded that starting or switching to insulin analogues was associated with improvement in glycemic control with low frequency of hypoglycemia. [source, 2015]
Insulin detemir has now become established as an effective basal insulin preparation and is widely used in the management of both type 1 and type 2 diabetes. [source, 2015]
Demonstrating this effect with Insulin detemir, however, has been unsuccessful in type 2 diabetes 34. [source, 2015]
Using a computer simulation model based on a subpopulation of the observational study PREDICTIVE, a German group modeled the long-term cost-effectiveness of conversion to Insulin detemir, with or without OADs, in patients failing OADs alone or in combination with NPH insulin or insulin glargine. [source, 2015]
Insulin analogs such as Insulin detemir and insulin glargine are widely used to treat diabetic patients and are very effective to lower fasting glucose (Pollock et al., 2011). [source, 2015]
A1chieve was a 24-week, prospective, open-label, non-interventional study conducted across four continents to examine the safety and effectiveness of BIAsp 30 (NovoMix® 30, Novo Nordisk A/S), Insulin detemir (Levemir®, Novo Nordisk A/S) and insulin Aspart (NovoRapid®, Novo Nordisk A/S), alone or in combination with basal insulin, in clinical practice. [source, 2015]
However, the contribution of insulin Aspart to effects on weight observed in these studies is impossible to separate from that of Insulin detemir. [source, 2015]
Therefore, using data from the A1chieve study in Korea, we investigated the effectiveness of the BI analog, Insulin detemir (Levemir®) in Korean patients with T2D. [source, 2015]
We also compared the effectiveness and safety of Insulin detemir according to the time of injection. [source, 2015]
The results showed no significant changes in various parameters of glycemic control, such as fasting plasma glucose, HbA1c, and glycosylated albumin, after switching to insulin degludec despite about 20% reduction in basal insulin dose at 12 weeks, indicating that insulin degludec has longer duration of action and a more potent glucose-lowering effect than insulin glargine or Insulin detemir. [source, 2015]